FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214878549> ?p ?o ?g. }

• W4214878549 endingPage "687" @default.
• W4214878549 startingPage "675" @default.
• W4214878549 abstract "High blood cholesterol accelerates the progression of atherosclerosis, which is an asymptomatic process lasting for decades. Rupture of atherosclerotic plaques induces thrombosis, which results in myocardial infarction or stroke. Lowering cholesterol levels is beneficial for preventing atherosclerotic cardiovascular disease.Low-density lipoprotein (LDL) receptor (LDLR) was used as bait to identify its binding proteins in the plasma, and the coagulation factor prekallikrein (PK; encoded by the KLKB1 gene) was revealed. The correlation between serum PK protein content and lipid levels in young Chinese Han people was then analyzed. To investigate the effects of PK ablation on LDLR and lipid levels in vivo, we genetically deleted Klkb1 in hamsters and heterozygous Ldlr knockout mice and knocked down Klkb1 using adeno-associated virus-mediated shRNA in rats. The additive effect of PK and proprotein convertase subtilisin/kexin 9 inhibition also was evaluated. In addition, we applied the anti-PK neutralizing antibody that blocked the PK and LDLR interaction in mice. Mice lacking both PK and apolipoprotein e (Klkb1-/-Apoe-/-) were generated to assess the role of PK in atherosclerosis.PK directly bound LDLR and induced its lysosomal degradation. The serum PK concentrations positively correlated with LDL cholesterol levels in 198 young Chinese Han adults. Genetic depletion of Klkb1 increased hepatic LDLR and decreased circulating cholesterol in multiple rodent models. Inhibition of proprotein convertase subtilisin/kexin 9 with evolocumab further decreased plasma LDL cholesterol levels in Klkb1-deficient hamsters. The anti-PK neutralizing antibody could similarly lower plasma lipids through upregulating hepatic LDLR. Ablation of Klkb1 slowed the progression of atherosclerosis in mice on Apoe-deficient background.PK regulates circulating cholesterol levels through binding to LDLR and inducing its lysosomal degradation. Ablation of PK stabilizes LDLR, decreases LDL cholesterol, and prevents atherosclerotic plaque development. This study suggests that PK is a promising therapeutic target to treat atherosclerotic cardiovascular disease." @default.
• W4214878549 created "2022-03-05" @default.
• W4214878549 creator A5001317899 @default.
• W4214878549 creator A5003642180 @default.
• W4214878549 creator A5011279839 @default.
• W4214878549 creator A5034582366 @default.
• W4214878549 creator A5041789458 @default.
• W4214878549 creator A5042131744 @default.
• W4214878549 creator A5047177665 @default.
• W4214878549 creator A5047585547 @default.
• W4214878549 creator A5047971898 @default.
• W4214878549 creator A5059439989 @default.
• W4214878549 creator A5069645681 @default.
• W4214878549 creator A5070702181 @default.
• W4214878549 creator A5074341982 @default.
• W4214878549 creator A5077340276 @default.
• W4214878549 creator A5083528210 @default.
• W4214878549 creator A5089296571 @default.
• W4214878549 creator A5090874503 @default.
• W4214878549 date "2022-03-01" @default.
• W4214878549 modified "2023-10-17" @default.
• W4214878549 title "Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis" @default.
• W4214878549 cites W1967508759 @default.
• W4214878549 cites W1971827979 @default.
• W4214878549 cites W1993916452 @default.
• W4214878549 cites W2006751286 @default.
• W4214878549 cites W2014314228 @default.
• W4214878549 cites W2015267683 @default.
• W4214878549 cites W2030341081 @default.
• W4214878549 cites W2033453343 @default.
• W4214878549 cites W2045387793 @default.
• W4214878549 cites W2047023619 @default.
• W4214878549 cites W2066963386 @default.
• W4214878549 cites W2078669364 @default.
• W4214878549 cites W2078678101 @default.
• W4214878549 cites W2083154566 @default.
• W4214878549 cites W2085237214 @default.
• W4214878549 cites W2102161788 @default.
• W4214878549 cites W2115772088 @default.
• W4214878549 cites W2122655704 @default.
• W4214878549 cites W2125850072 @default.
• W4214878549 cites W2140848039 @default.
• W4214878549 cites W2160347316 @default.
• W4214878549 cites W2166711199 @default.
• W4214878549 cites W2245918962 @default.
• W4214878549 cites W2394486600 @default.
• W4214878549 cites W2546192931 @default.
• W4214878549 cites W2609543937 @default.
• W4214878549 cites W2610203641 @default.
• W4214878549 cites W2621573467 @default.
• W4214878549 cites W2913953816 @default.
• W4214878549 cites W2919402721 @default.
• W4214878549 cites W2959202949 @default.
• W4214878549 cites W2979936870 @default.
• W4214878549 cites W2990871574 @default.
• W4214878549 cites W2996185966 @default.
• W4214878549 cites W3010522600 @default.
• W4214878549 cites W3023156691 @default.
• W4214878549 cites W3033499384 @default.
• W4214878549 cites W3037357689 @default.
• W4214878549 cites W3039255051 @default.
• W4214878549 cites W3080801838 @default.
• W4214878549 cites W3091126070 @default.
• W4214878549 cites W3093864427 @default.
• W4214878549 cites W3096585176 @default.
• W4214878549 cites W3120718347 @default.
• W4214878549 cites W3135316938 @default.
• W4214878549 cites W3155824129 @default.
• W4214878549 cites W3165590944 @default.
• W4214878549 doi "https://doi.org/10.1161/circulationaha.121.056491" @default.
• W4214878549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35189703" @default.
• W4214878549 hasPublicationYear "2022" @default.
• W4214878549 type Work @default.
• W4214878549 citedByCount "14" @default.
• W4214878549 countsByYear W42148785492022 @default.
• W4214878549 countsByYear W42148785492023 @default.
• W4214878549 crossrefType "journal-article" @default.
• W4214878549 hasAuthorship W4214878549A5001317899 @default.
• W4214878549 hasAuthorship W4214878549A5003642180 @default.
• W4214878549 hasAuthorship W4214878549A5011279839 @default.
• W4214878549 hasAuthorship W4214878549A5034582366 @default.
• W4214878549 hasAuthorship W4214878549A5041789458 @default.
• W4214878549 hasAuthorship W4214878549A5042131744 @default.
• W4214878549 hasAuthorship W4214878549A5047177665 @default.
• W4214878549 hasAuthorship W4214878549A5047585547 @default.
• W4214878549 hasAuthorship W4214878549A5047971898 @default.
• W4214878549 hasAuthorship W4214878549A5059439989 @default.
• W4214878549 hasAuthorship W4214878549A5069645681 @default.
• W4214878549 hasAuthorship W4214878549A5070702181 @default.
• W4214878549 hasAuthorship W4214878549A5074341982 @default.
• W4214878549 hasAuthorship W4214878549A5077340276 @default.
• W4214878549 hasAuthorship W4214878549A5083528210 @default.
• W4214878549 hasAuthorship W4214878549A5089296571 @default.
• W4214878549 hasAuthorship W4214878549A5090874503 @default.
• W4214878549 hasBestOaLocation W42148785491 @default.
• W4214878549 hasConcept C126322002 @default.
• W4214878549 hasConcept C134018914 @default.
• W4214878549 hasConcept C2778163477 @default.

• next